Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 29;19(11):3378. doi: 10.3390/ijms19113378

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Pretreatment of 786.0 xenografts expressing HIF2α with a nontoxic but molecularly effective dose of MSC sensitizes tumor cells to subsequent treatment with the combination of VEGF/VEGF receptor (VEGFR)-targeted agents and chemotherapy. Assessment of antitumor activity of MSC, SLM, Avastin, axitinib, sunitinib, and topotecan, administered individually to nude mice bearing 786.0 ccRCC tumors (A), and in combination with either MSC (B) or SLM (C), and in combination with axitinib (D). (E) Summary of the antitumor activity of MSC in sequential combination with anticancer therapies [83].